ICCC (ImmuCell) Non Operating Income: $-2.76 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ICCC ImmuCell Corp ICCC
51 GF Score
Price $10.02
GF Value $6.91
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is ImmuCell Non Operating Income?

ImmuCell ICCC -1.14% 51 Non Operating Income is $-2.76 Mil as of Jun. 2026. GuruFocus rates ICCC with a GF Score™ of 51/100 and a GF Value™ of $6.91 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. ImmuCell's Non Operating Income for the three months ended in Jun. 2026 was $-0.02 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-2.76 Mil.

ImmuCell Non Operating Income Related Terms

ImmuCell Non Operating Income Historical Data

* Premium members only.

The historical data trend for ImmuCell's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuCell Non Operating Income Chart

ImmuCell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 0.01 0.36 -0.02 -2.34

ImmuCell Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 -0.06 -2.71 0.04 -0.02
ICCC
51GF Score
ImmuCell Corp ICCC
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImmuCell Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $-2.76 Mil mean?
ImmuCell (ICCC) has a Non Operating Income of $-2.76 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on ImmuCell and its competitors.
Is ImmuCell's Non Operating Income too high?
ImmuCell's current Non Operating Income is $-2.76 Mil. Overall, ImmuCell has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ImmuCell's Non Operating Income compare to COYA and ENTX?
ImmuCell's Non Operating Income of $-2.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on ImmuCell and its competitors. ImmuCell's current Non Operating Income is $-2.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuCell stock overvalued right now?
Based on GuruFocus' analysis, ImmuCell (ICCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.91, compared to a current price of $10.02 — trading 44.9% above its estimated fair value. The current Non Operating Income is $-2.76 Mil. ImmuCell's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For ImmuCell (ICCC), the current Non Operating Income is $-2.76 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ImmuCell (ICCC) Overvalued in 2026?

Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued. The current stock price of $10.02 is trading 44.9% above its estimated GF Value™ of $6.91. GuruFocus considers ImmuCell to be Significantly Overvalued.

Key valuation signals for ICCC:

  • Non Operating Income: $-2.76 Mil
  • GF Value™: $6.91 vs. price of $10.02 (44.9% above fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the ICCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ImmuCell Business Description

Other Exchanges IUL:Germany
Address 56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
51GF Score

Get the complete analysis for ICCC

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.02
Price
$6.91
GF Value